Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
Open accessPublished version of a preprint
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Many anti-SARS-CoV-2 neutralizing antibodies target the ACE2-binding site on viral spike receptor-binding domains (RBDs). The most potent antibodies recognize exposed variable epitopes, often rendering them ineffective against other sarbecoviruses and SARS-CoV-2 variants. Class 4 anti-RBD antibodies against a less-exposed, but more-conserved, cryptic epitope could recognize newly-emergent zoonotic sarbecoviruses and variants, but usually show only weak neutralization potencies. We characterized two class 4 anti-RBD antibodies derived from COVID-19 donors that exhibited broad recognition and potent neutralization of zoonotic coronavirus and SARS-CoV-2 variants. C118-RBD and C022-RBD structures revealed CDRH3 mainchain H-bond interactions that extended an RBD β-sheet, thus reducing sensitivity to RBD sidechain changes, and epitopes that extended from the cryptic epitope to occlude ACE2 binding. A C118-spike trimer structure revealed rotated RBDs to allow cryptic epitope access and the potential for intra-spike crosslinking to increase avidity. These studies facilitate vaccine design and illustrate potential advantages of class 4 RBD-binding antibody therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guindon, S., Dufayard, J.-F., Lefort, V., Anisimova, M., Hordijk, W., & Gascuel, O. (2010) · Systematic Biology · doi:10.1093/sysbio/syq010 · Cited by 18,376 · cited 1×
“0 (Guindon et al., 2010) and visualized with PRESTO (http://www.”
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353 · cited 1×
“Data from single crystals were indexed and integrated in XDS (Kabsch, 2010) andmerged using AIMLESS inCCP4 (Winn et al., 2011) (Table S1).”
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
UCSF ChimeraX: Meeting modern challenges in visualization and analysis
Goddard, T. D., Huang, C. C., Meng, E. C., Pettersen, E. F., Couch, G. S., Morris, J. H., & Ferrin, T. E. (2018) · Protein Science · doi:10.1002/pro.3235 · Cited by 5,267
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
GISAID: Global initiative on sharing all influenza data – from vision to reality
Shu, Y., & McCauley, J. (2017) · Eurosurveillance · doi:10.2807/1560-7917.es.2017.22.13.30494 · Cited by 3,039
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 4×
“However, the ACE2-binding region of the RBD also tends to accumulate amino acid changes, as evidenced by substitutions identified in the current SARSCoV-2 variants of concern (Annavajhala et al., 2021; Faria et al., 2021; Rambaut et al., 2020; Tegally et al., 2020; Voloch et al., 2020; West et al., 2021; Zhang et al.,…”
InfluentialDetection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Self-citationStructural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599
Self-citationThe Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.012 · Cited by 1,420
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308 · cited 2×
“To further define the C022 and C118 antibody epitopes, we evaluated binding of C118 and C022 to a panel of RBDswith mutations chosen from circulating variants that conferred resistance to one or more classes of anti-RBD antibodies (Li et al., 2020; Starr et al., 2021b; Weisblum et al., 2020).”
Self-citationStructure-based design of prefusion-stabilized SARS-CoV-2 spikes
Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178 · cited 1×
“Despite both C118 and C022 engaging the a4 helix and residue R408RBD, mutations at this position known to affect class 1 and class 4 anti-RBD antibodies (Greaney et al., 2021) had no effect on these antibodies (Figure S2A).”
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140
Potently neutralizing and protective human antibodies against SARS-CoV-2
Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2548-6 · Cited by 1,041
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.036 · Cited by 897
Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795
Self-citationPre-fusion structure of a human coronavirus spike protein
Kirchdoerfer, R. N., Cottrell, C. A., Wang, N., Pallesen, J., Yassine, H. M., Turner, H. L., Corbett, K. S., Graham, B. S., McLellan, J. S., & Ward, A. B. (2016) · Nature · doi:10.1038/nature17200 · Cited by 765
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D. (2021) · Science · doi:10.1126/science.abf9302 · Cited by 743 · cited 2×
“In addition, C118 and C022 antibodies were not affected by naturally occurring RBDmutations that undermine the activity of several antibodies approved for therapeutic use (Hoffmann et al., 2021; Starr et al., 2021b).”
A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice
Leist, S. R., Dinnon, K. H., Schäfer, A., Tse, L. V., Okuda, K., Hou, Y. J., West, A., Edwards, C. E., Sanders, W., Fritch, E. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.050 · Cited by 613
Self-citationStructural basis of a shared antibody response to SARS-CoV-2
Yuan, M., Liu, H., Wu, N. C., Lee, C.-C. D., Zhu, X., Zhao, F., Huang, D., Yu, W., Hua, Y., Tien, H., et al. (2020) · Science · doi:10.1126/science.abd2321 · Cited by 589
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572
Self-citationUltrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
Tortorici, M. A., Beltramello, M., Lempp, F. A., Pinto, D., Dang, H. V., Rosen, L. E., McCallum, M., Bowen, J., Minola, A., Jaconi, S., et al. (2020) · Science · doi:10.1126/science.abe3354 · Cited by 510
Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil
Voloch, C. M., Silva F, R. D., de Almeida, L. G. P., Cardoso, C. C., Brustolini, O. J., Gerber, A. L., Guimarães, A. P. D. C., Mariani, D., Costa, R. M. D., Ferreira, O. C., et al. (2020) · doi:10.1101/2020.12.23.20248598 · Cited by 372
Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil
Voloch, C. M., da Silva Francisco, R., de Almeida, L. G. P., Cardoso, C. C., Brustolini, O. J., Gerber, A. L., Guimarães, A. P. D. C., Mariani, D., da Costa, R. M., Ferreira, O. C., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00119-21 · Cited by 372
Emergence of a Novel SARS-CoV-2 Variant in Southern California
Zhang, W., Davis, B. D., Chen, S. S., Sincuir Martinez, J. M., Plummer, J. T., & Vail, E. (2021) · JAMA · doi:10.1001/jama.2021.1612 · Cited by 371 · cited 3×
“However, the ACE2-binding region of the RBD also tends to accumulate amino acid changes, as evidenced by substitutions identified in the current SARSCoV-2 variants of concern (Annavajhala et al., 2021; Faria et al., 2021; Rambaut et al., 2020; Tegally et al., 2020; Voloch et al., 2020; West et al., 2021; Zhang et al.,…”
The antigenic anatomy of SARS-CoV-2 receptor binding domain
Dejnirattisai, W., Zhou, D., Ginn, H. M., Duyvesteyn, H. M. E., Supasa, P., Case, J. B., Zhao, Y., Walter, T. S., Mentzer, A. J., Liu, C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.032 · Cited by 371
Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.001 · Cited by 364 · cited 1×
“Consistent with their obligate role in viral entry, sarbecovirus S trimers are the primary targets of neutralizing antibodies (Brouwer et al., 2020; Cao et al., 2020; Fung and Liu, 2019; Kreer et al., 2020; Liu et al., 2020b; Robbiani et al., 2020; Rogers et al., 2020; Seydoux et al., 2020; Shi et al., 2020; Zost et a…”
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
Zhou, D., Duyvesteyn, H. M. E., Chen, C.-P., Huang, C.-G., Chen, T.-H., Shih, S.-R., Lin, Y.-C., Cheng, C.-Y., Cheng, S.-H., Huang, Y.-C., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0480-y · Cited by 274
Muecksch, F., Weisblum, Y., Barnes, C. O., Schmidt, F., Schaefer-Babajew, D., Lorenzi, J. C. C., Flyak, A. I., DeLaitsch, A. T., Huey-Tubman, K. E., Hou, S., et al. (2021) · doi:10.1101/2021.03.07.434227 · Cited by 39 · cited 3×
“The E484K substitution was constructed in the context of a pSARS-CoV-2-SD19 variant with a mutation in the furin cleavage site (R683G) to increase infectivity (Muecksch et al., 2021).”
Self-citationEmergence and Expansion of the SARS-CoV-2 Variant B.1.526 Identified in New York
Annavajhala, M. K., Mohri, H., Wang, P., Nair, M., Zucker, J. E., Sheng, Z., Gomez-Simmonds, A., Kelley, A. L., Tagliavia, M., Huang, Y., et al. (2021) · doi:10.1101/2021.02.23.21252259 · cited 6×
“…of the RBD also tends to accumulate amino acid changes, as evidenced by substitutions identified in the current SARSCoV-2 variants of concern (Annavajhala et al., 2021; Faria et al., 2021; Rambaut et al., 2020; Tegally et al., 2020; Voloch et al., 2020; West et al., 2021; Zhang et al.,…”
Influential
Research works printed but not linked: 68
- Adams, 2010, PHENIX: a comprehensive Python-based system for macromolecular structure solution, Acta Crystallogr. D Biol. Crystallogr., 66, 213, 10.1107/S0907444909052925 · DOI · Paper page
- Annavajhala, 2021, A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York, medRxiv
- Bell, 2016, High resolution single particle refinement in EMAN2.1, Methods, 100, 25, 10.1016/j.ymeth.2016.02.018 · DOI · Paper page
- Bunkóczi, 2011, Improvement of molecular-replacement models with Sculptor, Acta Crystallogr. D Biol. Crystallogr., 67, 303, 10.1107/S0907444910051218 · DOI · Paper page
- Cao, 2020, Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells, Cell, 182, 73, 10.1016/j.cell.2020.05.025 · DOI · Paper page
- Chan, 2020, Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2, Science, 369, 1261, 10.1126/science.abc0870 · DOI · Paper page
- Chen, 2010, MolProbity: all-atom structure validation for macromolecular crystallography, Acta Crystallogr. D Biol. Crystallogr., 66, 12, 10.1107/S0907444909042073 · DOI · Paper page
- Cohen, 2021, Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice, Science, 371, 735, 10.1126/science.abf6840 · DOI · Paper page
- Corti, 2010, Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine, J. Clin. Invest., 120, 1663, 10.1172/JCI41902 · DOI · Paper page
- Crawford, 2020, Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays, Viruses, 12, 513, 10.3390/v12050513 · DOI · Paper page
- Edgar, 2004, MUSCLE: multiple sequence alignment with high accuracy and high throughput, Nucleic Acids Res., 32, 1792, 10.1093/nar/gkh340 · DOI · Paper page
- Emsley, 2010, Features and development of Coot, Acta Crystallogr. D Biol. Crystallogr., 66, 486, 10.1107/S0907444910007493 · DOI · Paper page
- Fung, 2019, Human Coronavirus: Host-Pathogen Interaction, Annu. Rev. Microbiol., 73, 529, 10.1146/annurev-micro-020518-115759 · DOI · Paper page
- Goddard, 2007, Visualizing density maps with UCSF Chimera, J. Struct. Biol., 157, 281, 10.1016/j.jsb.2006.06.010 · DOI · Paper page
- Gristick, 2016, Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site, Nat. Struct. Mol. Biol., 23, 906, 10.1038/nsmb.3291 · DOI · Paper page
- Haagmans, 2014, Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation, Lancet Infect. Dis., 14, 140, 10.1016/S1473-3099(13)70690-X · DOI · Paper page
- Hoffmann, 2020, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052 · DOI · Paper page
- Huang, 2021, Breadth and function of antibody response to acute SARS-CoV-2 infection in humans, PLoS Pathog., 17, e1009352, 10.1371/journal.ppat.1009352 · DOI · Paper page
- Huo, 2020, Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike, Cell Host Microbe, 28, 445, 10.1016/j.chom.2020.06.010 · DOI · Paper page
- Kabsch, 2010, XDS, Acta Crystallogr. D Biol. Crystallogr., 66, 125, 10.1107/S0907444909047337 · DOI · Paper page
- Kane, 2016, Identification of Interferon-Stimulated Genes with Antiretroviral Activity, Cell Host Microbe, 20, 392, 10.1016/j.chom.2016.08.005 · DOI · Paper page
- Klein, 2010, Few and far between: how HIV may be evading antibody avidity, PLoS Pathog., 6, e1000908, 10.1371/journal.ppat.1000908 · DOI · Paper page
- Kreer, 2020, Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients, Cell, 182, 843, 10.1016/j.cell.2020.06.044 · DOI · Paper page
- Krissinel, 2007, Inference of macromolecular assemblies from crystalline state, J. Mol. Biol., 372, 774, 10.1016/j.jmb.2007.05.022 · DOI · Paper page
- Landau, 2005, ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures, Nucleic Acids Res., 33, W299, 10.1093/nar/gki370 · DOI · Paper page
- Lefranc, 2009, IMGT, the international ImMunoGeneTics information system, Nucleic Acids Res., 37, D1006, 10.1093/nar/gkn838 · DOI · Paper page
- Lefranc, 2015, IMGT®, the international ImMunoGeneTics information system® 25 years on, Nucleic Acids Res., 43, D413, 10.1093/nar/gku1056 · DOI · Paper page
- Li, 2003, Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature, 426, 450, 10.1038/nature02145 · DOI · Paper page
- Li, 2005, Bats are natural reservoirs of SARS-like coronaviruses, Science, 310, 676, 10.1126/science.1118391 · DOI · Paper page
- Li, 2019, The human coronavirus HCoV-229E S-protein structure and receptor binding, eLife, 8, e51230, 10.7554/eLife.51230 · DOI · Paper page
- Liu, 2020, Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity, Immunity, 53, 1272, 10.1016/j.immuni.2020.10.023 · DOI · Paper page
- Liu, 2021, A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection, Cell Host Microbe, 29, 806, 10.1016/j.chom.2021.04.005 · DOI · Paper page
- Mastronarde, 2005, Automated electron microscope tomography using robust prediction of specimen movements, J. Struct. Biol., 152, 36, 10.1016/j.jsb.2005.07.007 · DOI · Paper page
- McCoy, 2007, Phaser crystallographic software, J. Appl. Cryst., 40, 658, 10.1107/S0021889807021206 · DOI · Paper page
- Pear, 1993, Production of high-titer helper-free retroviruses by transient transfection, Proc. Natl. Acad. Sci. USA, 90, 8392, 10.1073/pnas.90.18.8392 · DOI · Paper page
- Pettersen, 2004, UCSF Chimera—a visualization system for exploratory research and analysis, J. Comput. Chem., 25, 1605, 10.1002/jcc.20084 · DOI · Paper page
- Piccoli, 2020, Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology, Cell, 183, 1024, 10.1016/j.cell.2020.09.037 · DOI · Paper page
- Punjani, 2017, cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination, Nat. Methods, 14, 290, 10.1038/nmeth.4169 · DOI · Paper page
- Rappazzo, 2021, Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody, Science, 371, 823, 10.1126/science.abf4830 · DOI · Paper page
- Rogers, 2020, Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model, bioRxiv
- Sauer, 2021, Structural basis for broad coronavirus neutralization, bioRxiv
- Schaefer, 2011, Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies, Proc. Natl. Acad. Sci. USA, 108, 11187, 10.1073/pnas.1019002108 · DOI · Paper page
- Scharf, 2015, Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env, Cell, 162, 1379, 10.1016/j.cell.2015.08.035 · DOI · Paper page
- Scheid, 2011, Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding, Science, 333, 1633, 10.1126/science.1207227 · DOI · Paper page
- Scheid, 2021, B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV, Cell, 184, 3205, 10.1016/j.cell.2021.04.032 · DOI
- Schoofs, 2019, Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope, Immunity, 50, 1513, 10.1016/j.immuni.2019.04.014 · DOI · Paper page
- Shah, 2021, The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic, Front. Immunol., 12, 637651, 10.3389/fimmu.2021.637651 · DOI
- Sievers, 2011, Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega, Mol. Syst. Biol., 7, 539, 10.1038/msb.2011.75 · DOI · Paper page
- Song, 2005, Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human, Proc. Natl. Acad. Sci. USA, 102, 2430, 10.1073/pnas.0409608102 · DOI · Paper page
- Starr, 2021, Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape, bioRxiv
- Terwilliger, 2018, A fully automatic method yielding initial models from high-resolution cryo-electron microscopy maps, Nat. Methods, 15, 905, 10.1038/s41592-018-0173-1 · DOI · Paper page
- Tortorici, 2021, Broad sarbecovirus neutralization by a human monoclonal antibody, Nature, 597, 103, 10.1038/s41586-021-03817-4 · DOI · Paper page
- Wagh, 2016, Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection, PLoS Pathog., 12, e1005520, 10.1371/journal.ppat.1005520 · DOI · Paper page
- Walls, 2016, Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer, Nature, 531, 114, 10.1038/nature16988 · DOI · Paper page
- Wang, 2017, Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies, eLife, 6, e27389, 10.7554/eLife.27389 · DOI
- Wang, 2018, Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China, Virol. Sin., 33, 104, 10.1007/s12250-018-0012-7 · DOI · Paper page
- Wang, 2021, A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies, Nat. Commun., 12, 1715, 10.1038/s41467-021-21968-w · DOI · Paper page
- Wec, 2020, Broad neutralization of SARS-related viruses by human monoclonal antibodies, Science, 369, 731, 10.1126/science.abc7424 · DOI · Paper page
- West, 2013, Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues, Proc. Natl. Acad. Sci. USA, 110, 10598, 10.1073/pnas.1309215110 · DOI
- West, 2021, SARS-CoV-2 lineage B.1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape, bioRxiv
- Wrapp, 2020, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, 367, 1260, 10.1126/science.abb2507 · DOI · Paper page
- Yan, 2020, Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2, Science, 367, 1444, 10.1126/science.abb2762 · DOI · Paper page
- Yuan, 2017, Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains, Nat. Commun., 8, 15092, 10.1038/ncomms15092 · DOI · Paper page
- Yuan, 2020, A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV, Science, 368, 630, 10.1126/science.abb7269 · DOI · Paper page
- Zhou, 2020, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579, 270, 10.1038/s41586-020-2012-7 · DOI · Paper page
- Zhou, 2021, Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses, bioRxiv
- Zivanov, 2018, New tools for automated high-resolution cryo-EM structure determination in RELION-3, eLife, 7, e42166, 10.7554/eLife.42166 · DOI · Paper page
- Zost, 2020, Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein, Nat. Med., 26, 1422, 10.1038/s41591-020-0998-x · DOI · Paper page
Cited by
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
McCallum, M., Czudnochowski, N., Rosen, L. E., Zepeda, S. K., Bowen, J. E., Walls, A. C., Hauser, K., Joshi, A., Stewart, C., Dillen, J. R., et al. (2022) · Science · doi:10.1126/science.abn8652 · Cited by 535
Fast, accurate antibody structure prediction from deep learning on massive set of natural antibodies
Ruffolo, J. A., Chu, L.-S., Mahajan, S. P., & Gray, J. J. (2023) · Nature Communications · doi:10.1038/s41467-023-38063-x · Cited by 316
Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
McCallum, M., Walls, A. C., Sprouse, K. R., Bowen, J. E., Rosen, L. E., Dang, H. V., De Marco, A., Franko, N., Tilles, S. W., Logue, J., et al. (2021) · Science · doi:10.1126/science.abl8506 · Cited by 288
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
Cohen, A. A., van Doremalen, N., Greaney, A. J., Andersen, H., Sharma, A., Starr, T. N., Keeffe, J. R., Fan, C., Schulz, J. E., Gnanapragasam, P. N. P., et al. (2022) · Science · doi:10.1126/science.abq0839 · Cited by 259
Self-citation
Metadata
- Authors
- Jette, C. A., Cohen, A. A., Gnanapragasam, P. N. P., Muecksch, F., Lee, Y. E., Huey-Tubman, K. E., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M. C., West, A. P., Keeffe, J. R., Bjorkman, P. J., & Barnes, C. O.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 36
- Issue
- 13
- Pages
- 109760
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W3198731203
- Cited by
- 116
- References
- 38
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Update notices
- erratum (2021-12-21)
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 3 d)
- Funders
- Rockefeller University
- California Institute of Technology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.